Research programme: autoimmune disorder therapeutics - Zymeworks
Latest Information Update: 01 Nov 2014
At a glance
- Originator Zymeworks
- Class Antibodies; Proteins
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Autoimmune disorders
Most Recent Events
- 01 Nov 2014 Early research in Autoimmune disorders in Canada (unspecified route)